235 related articles for article (PubMed ID: 32295224)
1. Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis.
Hurrell T; Kastrinou-Lampou V; Fardellas A; Hendriks DFG; Nordling Å; Johansson I; Baze A; Parmentier C; Richert L; Ingelman-Sundberg M
Cells; 2020 Apr; 9(4):. PubMed ID: 32295224
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
3. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
[TBL] [Abstract][Full Text] [Related]
4. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of 5-HT receptor antagonists in the regulation of fibrosis in a 3D human liver spheroid model.
Redenšek Trampuž S; van Riet S; Nordling Å; Ingelman-Sundberg M
Sci Rep; 2024 Jan; 14(1):1396. PubMed ID: 38228622
[TBL] [Abstract][Full Text] [Related]
6. The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model.
van Riet S; Julien A; Atanasov A; Nordling Å; Ingelman-Sundberg M
Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38358377
[TBL] [Abstract][Full Text] [Related]
7. Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.
Pingitore P; Sasidharan K; Ekstrand M; Prill S; Lindén D; Romeo S
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986904
[TBL] [Abstract][Full Text] [Related]
8. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development.
Davidson MD; Kukla DA; Khetani SR
Integr Biol (Camb); 2017 Aug; 9(8):662-677. PubMed ID: 28702667
[TBL] [Abstract][Full Text] [Related]
9. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
10. Modelling fatty liver disease with mouse liver-derived multicellular spheroids.
van Os EA; Cools L; Eysackers N; Szafranska K; Smout A; Verhulst S; Reynaert H; McCourt P; Mannaerts I; van Grunsven LA
Biomaterials; 2022 Nov; 290():121817. PubMed ID: 36208587
[TBL] [Abstract][Full Text] [Related]
11. Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells.
Kiagiadaki F; Kampa M; Voumvouraki A; Castanas E; Kouroumalis E; Notas G
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):891-899. PubMed ID: 29287776
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
15. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
[TBL] [Abstract][Full Text] [Related]
17. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
20. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
